Olalekan O Oluwole (Oluwole O Olalekan, Olalekan Oluwole)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 42

Top Topics

Acute Myeloid Leukemia

Stem Cell Transplantation

Epstein Barr Virus

Top Venues

Bone marrow transplantation

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Olalekan O Oluwole, Sattva S Neelapu, Markqayne D Ray, Eve H Limbrick-Oldfield, Sally W Wade, Steve Kanters, Anik R Patel, Frederick L Locke
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies. Expert review of anticancer therapy 24 (6) (2024)
Olalekan O Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M Vose, Nancy L Bartlett, Yi Lin, Abhinav Deol, Peter McSweeney, Andre H Goy, Marie José Kersten, Caron A Jacobson, Umar Farooq, Monique C Minnema, Catherine Thieblemont, John M Timmerman, Patrick Joseph Stiff, Irit Avivi, Dimitrios Tzachanis, Yan Zheng, Saran Vardhanabhuti, Jenny Nater, Rhine R Shen, Harry Miao, Jenny J Kim, Tom van Meerten
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone marrow transplantation 59 (3) (2024)
Olalekan O Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M Vose, Nancy L Bartlett, Yi Lin, Abhinav Deol, Peter McSweeney, Andre H Goy, Marie José Kersten, Caron A Jacobson, Umar Farooq, Monique C Minnema, Catherine Thieblemont, John M Timmerman, Patrick Joseph Stiff, Irit Avivi, Dimitrios Tzachanis, Yan Zheng, Saran Vardhanabhuti, Jenny Nater, Rhine R Shen, Harry Miao, Jenny J Kim, Tom van Meerten
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone marrow transplantation (2024)
Frederick L Locke, Olalekan O Oluwole, John G Kuruvilla, Catherine Thieblemont, Judith Trotman, Gilles Andre Salles, Steven P Rowe, Saran Vardhanabhuti, Joshua Winters, Simone Filosto, Christina To, Paul Cheng, Marco Schupp, Ronald Korn, Marie José Kersten
Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume. Blood 143 (24) (2024)
Frederick L Locke, Olalekan O Oluwole, John G Kuruvilla, Catherine Thieblemont, Judith Trotman, Gilles Andre Salles, Steven P Rowe, Saran Vardhanabhuti, Joshua Winters, Simone Filosto, Christina To, Paul Cheng, Marco Schupp, Ronald Korn, Marie José Kersten
Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume. Blood 143 (24) (2024)
Olalekan O Oluwole, Sattva S Neelapu, Markqayne D Ray, Eve H Limbrick-Oldfield, Sally W Wade, Steve Kanters, Anik R Patel, Frederick L Locke
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies. Expert review of anticancer therapy 24 (6) (2024)
Armin Ghobadi, Javier Munoz, Jason R Westin, Frederick L Locke, David Bernard Miklos, Aaron P Rapoport, Miguel-Ángel Perales, Patrick M Reagan, Joseph P McGuirk, Caron A Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O Oluwole
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood advances 8 (11) (2024)
Armin Ghobadi, Javier L Muñoz, Jason R Westin, Frederick L Locke, David Bernard Miklos, Aaron P Rapoport, Miguel-Ángel Perales, Patrick M Reagan, Joseph P McGuirk, Caron A Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O Oluwole
Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood advances (2024)
Olalekan O Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M Vose, Nancy L Bartlett, Yi Lin, Abhinav Deol, Peter McSweeney, Andre H Goy, Marie José Kersten, Caron A Jacobson, Umar Farooq, Monique C Minnema, Catherine Thieblemont, John M Timmerman, Patrick Joseph Stiff, Irit Avivi, Dimitrios Tzachanis, Yan Zheng, Saran Vardhanabhuti, Jenny Nater, Rhine R Shen, Harry Miao, Jenny J Kim, Tom van Meerten
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone marrow transplantation 59 (3) (2024)
Michael Montoya, Hannah J Harmsen, Brittney Baer, Nancy Long, Amy Messimore, Reena V Jayani, Adetola Kassim, Andrew P Jallouk, James H Jerkins, Eden A Biltibo, Bipin P Savani, Bhagirathbhai R Dholaria, Olalekan O Oluwole, David S Morgan
Progressive multifocal leukoencephalopathy after CAR-T cell therapy. Bone marrow transplantation (2024)
Michael D Jain, Jay Y Spiegel, Loretta J Nastoupil, John S Tamaresis, Armin Ghobadi, Yi Lin, Lazaros Lekakis, Patrick Reagan, Olalekan O Oluwole, Joseph P McGuirk, Abhinav Deol, Kathleen A Dorritie, Alison R Sehgal, Andre H Goy, Brian T Hill, Charalambos Andreadis, Javier L Muñoz, Matthew L Ulrickson, Jason R Westin, Julio C Chavez, Dilan A Patel, Miriam T Jacobs, Radhika Bansal, N Nora Bennani, Vivek G Patel, Aaron P Rapoport, Julie M Vose, David Bernard Miklos, Sattva S Neelapu, Frederick L Locke, Matthew Lunning, Saurabh Dahiya
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Olalekan O Oluwole, Sattva S Neelapu, Markqayne D Ray, Eve H Limbrick-Oldfield, Sally W Wade, Steve Kanters, Anik R Patel, Frederick L Locke
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies. Expert review of anticancer therapy 24 (6) (2024)
Nausheen Ahmed, William Wesson, Forat Lutfi, David L Porter, Veronika Bachanova, Loretta J Nastoupil, Miguel-Ángel Perales, Richard T Maziarz, Jamie Brower, Gunjan L Shah, Andy I Chen, Olalekan O Oluwole, Stephen J Schuster, Michael R Bishop, Joseph P McGuirk, Peter A Riedell
Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel. Blood advances (2024)
Olalekan O Oluwole, Markqayne D Ray, Neil Davies, Rory Bradford, Calum Jones, Anik R Patel, Frederick L Locke
Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results. Journal of medical economics (2024)
Armin Ghobadi, Javier Munoz, Jason R Westin, Frederick L Locke, David Bernard Miklos, Aaron P Rapoport, Miguel-Ángel Perales, Patrick M Reagan, Joseph P McGuirk, Caron A Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O Oluwole
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood advances 8 (11) (2024)
Olalekan O Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M Vose, Nancy L Bartlett, Yi Lin, Abhinav Deol, Peter McSweeney, Andre H Goy, Marie José Kersten, Caron A Jacobson, Umar Farooq, Monique C Minnema, Catherine Thieblemont, John M Timmerman, Patrick Joseph Stiff, Irit Avivi, Dimitrios Tzachanis, Yan Zheng, Saran Vardhanabhuti, Jenny Nater, Rhine R Shen, Harry Miao, Jenny J Kim, Tom van Meerten
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone marrow transplantation (2024)
Michael D Jain, Jay Y Spiegel, Loretta J Nastoupil, John S Tamaresis, Armin Ghobadi, Yi Lin, Lazaros Lekakis, Patrick Reagan, Olalekan O Oluwole, Joseph P McGuirk, Abhinav Deol, Kathleen A Dorritie, Alison R Sehgal, Andre H Goy, Brian T Hill, Charalambos Andreadis, Javier L Muñoz, Matthew L Ulrickson, Jason R Westin, Julio C Chavez, Dilan A Patel, Miriam T Jacobs, Radhika Bansal, N Nora Bennani, Vivek G Patel, Aaron P Rapoport, Julie M Vose, David Bernard Miklos, Sattva S Neelapu, Frederick L Locke, Matthew Lunning, Saurabh Dahiya
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Frederick L Locke, Olalekan O Oluwole, John G Kuruvilla, Catherine Thieblemont, Judith Trotman, Gilles Andre Salles, Steven P Rowe, Saran Vardhanabhuti, Joshua Winters, Simone Filosto, Christina To, Paul Cheng, Marco Schupp, Ronald Korn, Marie José Kersten
Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume. Blood 143 (24) (2024)
Olalekan O Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M Vose, Nancy L Bartlett, Yi Lin, Abhinav Deol, Peter McSweeney, Andre H Goy, Marie José Kersten, Caron A Jacobson, Umar Farooq, Monique C Minnema, Catherine Thieblemont, John M Timmerman, Patrick Joseph Stiff, Irit Avivi, Dimitrios Tzachanis, Yan Zheng, Saran Vardhanabhuti, Jenny Nater, Rhine R Shen, Harry Miao, Jenny J Kim, Tom van Meerten
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone marrow transplantation 59 (3) (2024)
Armin Ghobadi, Javier Munoz, Jason R Westin, Frederick L Locke, David Bernard Miklos, Aaron P Rapoport, Miguel-Ángel Perales, Patrick M Reagan, Joseph P McGuirk, Caron A Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O Oluwole
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood advances 8 (11) (2024)
Olalekan O Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M Vose, Nancy L Bartlett, Yi Lin, Abhinav Deol, Peter McSweeney, Andre H Goy, Marie José Kersten, Caron A Jacobson, Umar Farooq, Monique C Minnema, Catherine Thieblemont, John M Timmerman, Patrick Joseph Stiff, Irit Avivi, Dimitrios Tzachanis, Yan Zheng, Saran Vardhanabhuti, Jenny Nater, Rhine R Shen, Harry Miao, Jenny J Kim, Tom van Meerten
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone marrow transplantation 59 (3) (2024)
Armin Ghobadi, Javier Munoz, Jason R Westin, Frederick L Locke, David Bernard Miklos, Aaron P Rapoport, Miguel-Ángel Perales, Patrick M Reagan, Joseph P McGuirk, Caron A Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O Oluwole
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood advances 8 (11) (2024)
Olalekan O Oluwole, Markqayne D Ray, Neil Davies, Rory Bradford, Calum Jones, Anik R Patel, Frederick L Locke
Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results. Journal of medical economics 27 (1) (2024)
Olalekan O Oluwole, Markqayne D Ray, Neil Davies, Rory Bradford, Calum Jones, Anik R Patel, Frederick L Locke
Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results. Journal of medical economics 27 (1) (2024)
Olalekan O Oluwole, Sattva S Neelapu, Markqayne D Ray, Eve H Limbrick-Oldfield, Sally W Wade, Steve Kanters, Anik R Patel, Frederick L Locke
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies. Expert review of anticancer therapy (2024)
Frederick L Locke, Olalekan O Oluwole, John Kuruvilla, Catherine Thieblemont, Judith Trotman, Gilles Andre Salles, Steven P Rowe, Saran Vardhanabhuti, Joshua Winters, Simone Filosto, Christina To, Paul Cheng, Marco Schupp, Ronald Korn, Marie José Kersten
Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume. Blood (2024)
Sattva S Neelapu, Caron A Jacobson, Armin Ghobadi, David Bernard Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman, Abhinav Deol, Patrick M Reagan, Patrick Joseph Stiff, Ian W Flinn, Umar Farooq, Andre H Goy, Peter McSweeney, Javier L Muñoz, Tanya Siddiqi, Julio C Chavez, Alex F Herrera, Nancy L Bartlett, Adrian A Bot, Rhine R Shen, Jinghui Dong, Kanwarjit Singh, Harry Miao, Jenny J Kim, Yan Zheng, Frederick L Locke
5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1). Blood (2023)
Yucai Wang, Preetesh Jain, Frederick L Locke, Matthew John Maurer, Matthew J Frank, Javier L Muñoz, Saurabh Dahiya, Amer M Beitinjaneh, Miriam T Jacobs, Joseph P McGuirk, Julie M Vose, Andre H Goy, Charalambos Andreadis, Brian T Hill, Kathleen A Dorritie, Olalekan O Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent P Wang, Rahul Banerjee, David Bernard Miklos, Aaron P Rapoport, Lazaros Lekakis, Armin Ghobadi, Sattva S Neelapu, Yi Lin, Michael L Wang, Michael D Jain
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Sattva S Neelapu, Julio C Chavez, Alison Sehgal, Narendranath Epperla, Matthew L Ulrickson, Emmanuel Bachy, Pashna Munshi, Carla Casulo, David G Maloney, Sven de Vos, Ran Reshef, Lori A Leslie, Olalekan O Oluwole, Ibrahim Yakoubagha, Rashmi Khanal, Joseph D Rosenblatt, Ronald Korn, Weixing Peng, Christine Lui, Jacob Wullf, Rhine R Shen, Soumya Poddar, A Scott Jung, Harry Miao, Sara Beygi, Caron A Jacobson
Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5). Blood (2023)
Michael D Jain, Miriam T Jacobs, Feng Gao, Loretta J Nastoupil, Jay Y Spiegel, Yi Lin, Saurabh Dahiya, Matthew A Lunning, Lazaros J Lekakis, Patrick M Reagan, Olalekan O Oluwole, Joseph P McGuirk, Abhinav Deol, Alison Sehgal, Andre H Goy, Brian T Hill, Charalambos Andreadis, Javier L Muñoz, Julio C Chavez, N Nora Bennani, Aaron P Rapoport, Julie M Vose, David Bernard Miklos, Sattva S Neelapu, Frederick L Locke, Armin Ghobadi
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results from the US lymphoma CAR-T consortium. Blood advances (2023)
Jason R Westin, Frederick L Locke, Michael J Dickinson, Armin Ghobadi, Mahmoud Elsawy, Tom van Meerten, David Bernard Miklos, Matthew L Ulrickson, Miguel-Ángel Perales, Umar Farooq, Luciano Wannesson, Lori A Leslie, Marie José Kersten, Caron A Jacobson, John M Pagel, Gerald Georg Wulf, Patrick B Johnston, Aaron P Rapoport, Linqiu Du, Saran Vardhanabhuti, Simone Filosto, Jina Shah, Julia Thornton Snider, Paul Cheng, Christina To, Olalekan O Oluwole, Anna Sureda
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Olalekan O Oluwole, Jenny M H Chen, Keith Chan, Anik R Patel, Jeroen P Jansen, Sam Keeping, Yan Zheng, Julia Thornton Snider, Frederick L Locke
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma. Leukemia & lymphoma (2022)
Kitsada Wudhikarn, Ana Alarcon Tomas, Jessica R Flynn, Sean M Devlin, Jamie Brower, Veronika Bachanova, Loretta J Nastoupil, Joseph P McGuirk, Richard T Maziarz, Olalekan O Oluwole, Stephen J Schuster, David L Porter, Michael R Bishop, Peter A Riedell, Miguel-Ángel Perales
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood advances (2022)
Jennifer Marvin-Peek, Bipin P Savani, Olalekan O Oluwole, Bhagirathbhai R Dholaria
Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia. Cancers 14 (3) (2022)
Olalekan O Oluwole, Rongzhe Liu, Ibrahim Diakite, Chaoling Feng, Anik Patel, Iman Nourhussein, Julia Thornton Snider, Frederick L Locke
Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. Journal of medical economics 25 (1) (2022)
Shakthi T Bhaskar, Vivek G Patel, David L Porter, Stephen J Schuster, Loretta J Nastoupil, Miguel-Ángel Perales, Ana Alarcon Tomas, Michael R Bishop, Joseph P McGuirk, Richard T Maziarz, Andy Chen, Veronika Bachanova, Joseph Maakaron, Peter A Riedell, Olalekan O Oluwole
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood advances (2022)
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, Patrick M Reagan, David Bernard Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin, Michael Crump, John Kuruvilla, Eric Van Den Neste, Umar Farooq, Lynn Navale, Venita DePuy, Jenny J Kim, Christian Gisselbrecht
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood advances 5 (20) (2021)
Shakthi T Bhaskar, Bhagirathbhai R Dholaria, Salyka M Sengsayadeth, Bipin N Savani, Olalekan O Oluwole
Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem 3 (Suppl 1) (2021)
Rongzhe Liu, Olalekan O Oluwole, Ibrahim Diakite, Marc F Botteman, Julia Thornton Snider, Frederick L Locke
Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. Journal of medical economics 24 (1) (2021)
Katie S Gatwood, Bhagirathbhai R Dholaria, Mariana Lucena, Brittney Baer, Bipin N Savani, Olalekan O Oluwole
Chimeric antigen receptor T-cell therapy: Challenges and framework of outpatient administration. EJHaem 3 (Suppl 1) (2021)
Bijal D Shah, Michael R Bishop, Olalekan O Oluwole, Aaron C Logan, Maria R Baer, William B Donnellan, Kristen M O'Dwyer, Houston Holmes, Martha L Arellano, Armin Ghobadi, John M Pagel, Yi Lin, Ryan D Cassaday, Jae H Park, Mehrdad Abedi, Januario E Castro, Daniel J DeAngelo, Adriana K Malone, Raya Mawad, Gary J Schiller, John M Rossi, Adrian Bot, Tong Shen, Lovely Goyal, Rajul K Jain, Remus Vezan, William G Wierda
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood 138 (1) (2021)
Jeremy W Jacobs, Rahul Ramaswamy, Vanessa States, Jennifer Reppucci, Olalekan O Oluwole, Emily F Mason, Mary Ann Thompson
Chronic myeloid leukemia with pure erythroid leukemia blast crisis. Leukemia & lymphoma (2021)